Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4348723 | 0.89 | ESR1 (0.52) | ACHETSHRKMT2ACYP3A4HTT | |
| SCHEMBL3947712 | 0.89 | ESR1 (0.52) | ACHETSHRKMT2ACYP3A4HTT | |
| SCHEMBL4942966 | 0.87 | TSHR (0.67) | ACHETSHRCYP3A4LMNAESR1 | |
| SCHEMBL18901114 | 0.87 | TSHR (0.67) | ACHETSHRCYP3A4LMNAESR1 | |
| SCHEMBL12937240 | 0.82 | SMN1; SMN2 (0.53) | ACHETSHRKMT2ACYP3A4LMNA | |
| SCHEMBL7025938 | 0.81 | — | — | |
| SCHEMBL12689 | 0.81 | — | — | |
| SCHEMBL17931719 | 0.80 | ESR1 (0.60) | TSHRNFE2L2KMT2ACYP3A4LMNA | |
| SCHEMBL7938348 | 0.80 | PAX8 (0.44) | TSHRKMT2ACYP3A4HTTESR1 | |
| SCHEMBL24522303 | 0.79 | TSHR (0.83) | ACHETSHRCYP3A4LMNAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
| EP-2632261-B1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9309260-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2015176978-A1 | PIPERIDINE-BASED STABILIZERS AND POLYMERS END-CAPPED WITH THE SAME | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2015-11-26 | — | — | WO | disclosed |
| US-9085587-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130302282-A1 | Inhibitors of Hepatitis C Virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-6242654-B1 | REACTING A PHENOLATE COMPOUND WITH AN ORGANIC FLUORINATING AGENT TO PREPARE A FLUORINE SUBSTITUTED AROMATIC COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-1013629-A1 | Preparation process of fluorine subsituted aromatic compound | Mitsui Chemicals, Inc. (JP) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302282-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, LIPC, HCCS | ACHE 2816/4885TSHR 4726/4885NFE2L2 4000/4885 |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ACHE 4738/4885TSHR 1187/4885NFE2L2 2095/4885 |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | ACHE 4738/4885TSHR 1187/4885NFE2L2 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.